Biological activity of cadeguomycin. Inhibition of tumor growth and metastasis, immunostimulation, and potentiation of 1-beta-D-arabinofuranosylcytosine.
Cadeguomycin retarded growth of sc solid IMC carcinoma in CDF1 mice, and pulmonary metastasis of Lewis lung carcinoma in C57BL/6 mice. The antibiotic enhanced phagocytic activity of murine peritoneal macrophages and IL-1 production by P388D1 cells. Delayed type hypersensitivity was stimulated and interferon was induced by the drug. The results suggest that cadeguomycin inhibits tumor growth and metastasis in association with modification of the immune system. The cytotoxicity of arabinosylcytosine to K562 and YAC-1 cells was markedly enhanced by cadeguomycin in culture. The combined administration of arabinosylcytosine and cadeguomycin displayed potentiation in the inhibition of growth of ip-implanted P388 leukemia and metastasis of sc-implanted P388 leukemia to the regional lymph nodes. Cadeguomycin showed low toxicity for mice.
Yuan
B D
BD
Wu
R T
RT
Sato
I
I
Okabe
T
T
Suzuki
H
H
Nishimura
T
T
Tanaka
N
N
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D003561:Cytarabine / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D006151:Guanosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000633:toxicity; D006801:Humans; D007372:Interferons / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000556:secondary; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010587:Phagocytosis / Q000187:drug effects
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D007375:Interleukin-1; D003561:Cytarabine; D006151:Guanosine; C034568:cadeguomycin; D007372:Interferons